InvestorsHub Logo
Followers 19
Posts 1027
Boards Moderated 0
Alias Born 06/28/2013

Re: trebor4 post# 10077

Thursday, 03/20/2014 10:02:03 PM

Thursday, March 20, 2014 10:02:03 PM

Post# of 48316
I guess i don't understand why it would have to be MCC only. Wouldn't final melanoma p2 data Combined with our addition of the anti-pd-1s be fine?, meaning wouldn't presenting a more cohesive plan of our overall treatments be more likely? And wouldn't presentation of new data/treatment plans include elaboration of past data as well?